Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells $134,978.97 in Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 47,031 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $2.87, for a total value of $134,978.97. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mary E. Godwin also recently made the following trade(s):

• On Tuesday, September 17th, Mary E. Godwin sold 35,000 shares of Nautilus Biotechnology stock. The shares were sold at an average price of $2.85, for a total value of $99,750.00.

Nautilus Biotechnology Stock Performance

Shares of NAUT stock opened at $2.91 on Friday. The stock’s 50-day simple moving average is $2.62 and its 200-day simple moving average is $2.60. The firm has a market capitalization of $364.94 million, a PE ratio of -5.29 and a beta of 1.20. Nautilus Biotechnology, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $3.45.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its earnings results on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. During the same period in the previous year, the company posted ($0.13) earnings per share. Sell-side analysts forecast that Nautilus Biotechnology, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Jefferies Financial Group assumed coverage on Nautilus Biotechnology in a report on Monday, June 3rd. They issued a “hold” rating and a $3.00 price objective on the stock. Guggenheim assumed coverage on Nautilus Biotechnology in a report on Thursday, June 27th. They issued a “buy” rating and a $6.00 price objective on the stock.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after buying an additional 4,239 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Nautilus Biotechnology by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock worth $71,000 after buying an additional 9,624 shares during the last quarter. Renaissance Technologies LLC boosted its position in Nautilus Biotechnology by 11.2% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares in the last quarter. Clarius Group LLC boosted its position in Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after purchasing an additional 16,661 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Nautilus Biotechnology by 1.0% during the first quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock worth $8,407,000 after purchasing an additional 29,604 shares in the last quarter. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.